Breathing new insights into the role of mutant p53 in lung cancer.

IF 6.9 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Oncogene Pub Date : 2024-11-20 DOI:10.1038/s41388-024-03219-6

Tianwei Chen, Lauren M Ashwood, Olga Kondrashova, Andreas Strasser, Gemma Kelly, Kate D Sutherland

引用次数: 0

Abstract

The tumour suppressor gene p53 is one of the most frequently mutated genes in lung cancer and these defects are associated with poor prognosis, albeit some debate exists in the lung cancer field. Despite extensive research, the exact mechanisms by which mutant p53 proteins promote the development and sustained expansion of cancer remain unclear. This review will discuss the cellular responses controlled by p53 that contribute to tumour suppression, p53 mutant lung cancer mouse models and characterisation of p53 mutant lung cancer. Furthermore, we discuss potential approaches of targeting mutant p53 for the treatment of lung cancer.

查看原文本刊更多论文

对突变 p53 在肺癌中的作用有了新的认识。

肿瘤抑制基因 p53 是肺癌中最常见的突变基因之一，这些缺陷与预后不良有关，尽管在肺癌领域还存在一些争论。尽管进行了广泛的研究，但突变的 p53 蛋白促进癌症发展和持续扩大的确切机制仍不清楚。本综述将讨论由 p53 控制的有助于抑制肿瘤的细胞反应、p53 突变肺癌小鼠模型以及 p53 突变肺癌的特征。此外，我们还将讨论针对突变 p53 治疗肺癌的潜在方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncogene 医学-生化与分子生物学

CiteScore

15.30

自引率

1.20%

发文量

404

审稿时长

1 months

期刊介绍： Oncogene is dedicated to advancing our understanding of cancer processes through the publication of exceptional research. The journal seeks to disseminate work that challenges conventional theories and contributes to establishing new paradigms in the etio-pathogenesis, diagnosis, treatment, or prevention of cancers. Emphasis is placed on research shedding light on processes driving metastatic spread and providing crucial insights into cancer biology beyond existing knowledge. Areas covered include the cellular and molecular biology of cancer, resistance to cancer therapies, and the development of improved approaches to enhance survival. Oncogene spans the spectrum of cancer biology, from fundamental and theoretical work to translational, applied, and clinical research, including early and late Phase clinical trials, particularly those with biologic and translational endpoints.